Price
5,828.5
-0.07%52W Range
Market Cap
₹9,674.95 Cr
Traded: ₹4.23 Cr (0.04%) 0.0x
Free Float: ₹2,845.40 Cr (0.15% of FF traded)
Volume · 60D trend
7.24 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +31.0% | +35.0% | +43.0% | -- | -- | Accelerating |
| Return | +24.0% | +2.0% | +4.0% | -1.0% | -- | Stable |
| Profit | +20.0% | +5.0% | +19.0% | -- | +11.0% | Stable |
| Sales | +4.0% | +1.0% | +8.0% | -- | +13.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 364 | 370 | 374 | 325 | 339 | 311 | 310 | 313 | 284 | 252 | 310 | 305 | 301 | 321 |
| Expenses | 264 | 235 | 263 | 205 | 248 | 230 | 186 | 199 | 236 | 185 | 208 | 216 | 256 | 241 |
| Operating Profit | 100 | 136 | 110 | 120 | 90 | 81 | 123 | 114 | 48 | 67 | 102 | 89 | 45 | 80 |
| OPM % | 27.0% | 37.0% | 30.0% | 37.0% | 27.0% | 26.0% | 40.0% | 36.0% | 17.0% | 27.0% | 33.0% | 29.0% | 15.0% | 25.0% |
| Other Income | 36 | 4 | 4 | 5 | 4 | 3 | 4 | 3 | -18 | 2 | 5 | 6 | 5 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 6 |
| Profit Before Tax | 129 | 133 | 109 | 119 | 89 | 79 | 122 | 111 | 23 | 63 | 100 | 88 | 44 | 79 |
| Tax % | 26.0% | 29.0% | 29.0% | 26.0% | 25.0% | 22.0% | 25.0% | 26.0% | 26.0% | 26.0% | 28.0% | 26.0% | 32.0% | 25.0% |
| Net Profit | 96 | 95 | 78 | 89 | 66 | 61 | 91 | 82 | 17 | 47 | 72 | 66 | 30 | 59 |
| Exceptional Items | 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 57.9 | 57.0 | 46.7 | 53.3 | 39.9 | 36.9 | 54.8 | 49.6 | 10.1 | 28.1 | 43.4 | 39.5 | 18.0 | 35.7 |
| Sales Growth (YoY) | 7.4% | 19.0% | 20.6% | 3.8% | 19.4% | 23.4% | 0.0% | 2.6% | -5.7% | -21.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -1.6% | -1.1% | 15.1% | -4.1% | 9.0% | 0.3% | -1.0% | 10.2% | 12.7% | -18.7% | 1.6% | 1.3% | -6.2% | -- |
| OP Growth (YoY) | 11.1% | 67.9% | -10.6% | 5.3% | 87.5% | 20.9% | 20.6% | 28.1% | 6.7% | -16.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | -26.5% | 23.6% | -8.3% | 33.3% | 11.1% | -34.1% | 7.9% | 137.5% | -28.4% | -34.3% | 14.6% | 97.8% | -43.8% | -- |
| Profit Growth (YoY) | -- | 55.0% | -15.0% | 8.0% | 158.0% | 31.0% | 26.0% | 26.0% | -14.0% | -21.0% | -6.0% | 3.0% | -28.0% | 16.0% |
| EPS Growth (YoY) | 45.3% | 54.6% | -14.7% | 7.5% | 294.4% | 31.4% | 26.1% | 25.6% | -43.7% | -21.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 1.6% | 21.9% | -12.4% | 33.8% | 8.2% | -32.7% | 10.4% | 390.6% | -64.0% | -35.4% | 9.9% | 119.9% | -49.6% | -- |
| OP Margin | 27.5% | 36.8% | 29.4% | 36.9% | 26.6% | 26.1% | 39.7% | 36.4% | 16.9% | 26.6% | 32.9% | 29.2% | 14.9% | 24.9% |
| Net Margin | 26.4% | 25.7% | 20.9% | 27.4% | 19.5% | 19.6% | 29.4% | 26.2% | 6.0% | 18.6% | 23.2% | 21.6% | 10.0% | 18.4% |
| Material Cost % | -- | 25.1% | 29.4% | 21.1% | 27.8% | 31.7% | 24.4% | 28.1% | 27.9% | 29.3% | 29.2% | 28.6% | 31.2% | 31.2% |
| Employee Cost % | -- | 13.7% | 16.5% | 16.6% | 16.5% | 15.7% | 15.2% | 14.8% | 17.1% | 19.2% | 18.5% | 19.9% | 18.4% | 18.9% |
| P/S | 6.75 | 7.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 27.11 | 32.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 18.43 | 20.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.
The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.
Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.
Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.
Record Date for Purpose of Dividend
Unaudited Financial Results for the Quarter ended June 30, 2026
Outcome of Board Meeting.
Dear Sir/Madam, Please find attached intimation regarding change in Company''s Annual General Meeting date for the Financial Year 2025-26 and record date for purpose of AGM/distribution ....
Dear Sir, Please find attached signed certificate for confirming compliance under Regulation 74 (5) of the SEBI (DP) Regulations, for the quarter ended June 30, 2026.
Dear Sir, Please find attached our intimation for closure of trading window.
Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of final dividend income from the Company, if approved by the shareholders at the ensuing AGM.
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Dear Sir, In terms ....
Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you regarding changes in the Senior Management Personnel of the Company shall take place effective July 1, 2026.
The Company has informed the Stock Exchange regarding the transcript and link to the recording of the analyst/institutional investors meeting held earlier today.
The Company has informed the Stock Exchange regarding the Presentation of the Analyst/Institutional investor meet scheduled to be held today.
Please find attached signed Annual Secretarial Compliance report for the year ended March 31, 2026
Record date for purpose of dividend
Dear Sir, Please find attached audited financial results for the year ended March 31, 2026.
Board has recommended final dividend for the Financial Year 2025-26, subject to approval of shareholders.
Dear Sir, Please find attached intimation for re appointment of Independent Director.
Please find attached press release for the quarter and financial year ended March 31, 2026.
We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board ....
Dear Sir, Please find attached our intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015. Request you to kindly take the same on record.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Dear Sir/Madam, Please find attached disclosure under regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended March 31, 2026.
Intimation for closure of trading window
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Intimation of Board ....
Board has approved record date for the purpose of distribution of interim dividend for the Financial year 2025-26.
Board approves interim dividend of Rs. 160 (including one time special dividend of Rs. 50) per share.
Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of dividend income from declaration of interim dividend for the Financial year 2025-26.
Press release for the unaudited financial results for the quarter ended December 31, 2025
Unaudited financial results for the quarter ended December 31, 2025 along with limited review report issued by the statutory auditors.
We are enclosing herewith the following: a. Unaudited Financial Results; b. Limited Review Report in respect of the Unaudited Financial Results furnished by Statutory Auditors of the ....
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Update on board meeting ....
Dear Sir, Please find attached compliance certificate under regulation 74(5) of SEBI (DP) Regulations.
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve The meeting of the ....
Dear Sir, Please find attached intimation for closure of trading window for the quarter to be ended on December 31, 2025.
Dear Sir, Please find attached revised outcome of the postal ballot results declared on November 17, 2025, as advised by the exchange.
Approval of shareholders for appointment of Mr. Shashank Srowthy as an Executive Director of the Company, via postal ballot.
Voting results along with report of the scrutinizer for the postal ballot completed on November 16, 2025
We enclose herewith Press Release regarding the unaudited financial results for quarter ended September 30, 2025.
Outcome of Board Meeting held for the quarter ended September 30, 2025
Outcome of Board Meeting for the quarter ended September 30, 2025
Purpose of the meeting has been revised
Please find attached report for the quarter ended September 30, 2025
Intimation of allotment of DIN to Mr. Shashank Srowthy, Executive Director
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and approve Intimation of Board ....
Intimation for closure of Trading window for the quarter ended September 30, 2025
Change in senior management personnel of the Company
Mr. Lokesh Chandak has stepped down as Chief Financial Officer of the Company as he will be moving onto his new assignment in P&G.
Annual Reports
14Credit Ratings
5Concalls
4Held by ETFs
1 ETFs hold PGHL · sorted by weight
Held by Mutual Funds
10 schemes hold PGHL · sorted by weight